GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (OTCPK:GLPGF) » Definitions » Gross Margin %

Galapagos NV (Galapagos NV) Gross Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Galapagos NV Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Galapagos NV's Gross Profit for the three months ended in Dec. 2023 was $-228.1 Mil. Galapagos NV's Revenue for the three months ended in Dec. 2023 was $-228.1 Mil. Therefore, Galapagos NV's Gross Margin % for the quarter that ended in Dec. 2023 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Galapagos NV's Gross Margin % or its related term are showing as below:

GLPGF' s Gross Margin % Range Over the Past 10 Years
Min: 94.35   Med: 205.3   Max: 206.16
Current: 94.35


During the past 13 years, the highest Gross Margin % of Galapagos NV was 206.16%. The lowest was 94.35%. And the median was 205.30%.

GLPGF's Gross Margin % is ranked better than
92.38% of 735 companies
in the Biotechnology industry
Industry Median: 59.4 vs GLPGF: 94.35

Galapagos NV had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Galapagos NV was 0.00% per year.


Galapagos NV Gross Margin % Historical Data

The historical data trend for Galapagos NV's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Gross Margin % Chart

Galapagos NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 206.16 204.44 -

Galapagos NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -53.86 98.00 97.15 95.25 -

Competitive Comparison of Galapagos NV's Gross Margin %

For the Biotechnology subindustry, Galapagos NV's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Gross Margin % falls into.



Galapagos NV Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Galapagos NV's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=261.4 / 261.422
=(Revenue - Cost of Goods Sold) / Revenue
=(261.422 - 0) / 261.422
=N/A %

Galapagos NV's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-228.1 / -228.052
=(Revenue - Cost of Goods Sold) / Revenue
=(-228.052 - 0) / -228.052
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Galapagos NV  (OTCPK:GLPGF) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Galapagos NV had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Galapagos NV Gross Margin % Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV (Galapagos NV) Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.